Abe Fda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Most. the fda leadership, new leadership of the -- under the democrats will make the decision about what to do next. everybody's looking at it as an indication of the foorm suit call condition. >> should be interesting. bob bazell visiting us in the washington newsroom. >> better than the tarmac, i'll tell you. >> very nice. coming up, is there a civil war between the white house and house democrats? probably not. we'll go to the course, congressman van holland tasked with keeping democrats in control of the house. but first, a look ahead at the president's schedule. as you know, he comes ...

Will it happen? this is the holy grail of the pharmaceutical industry, is it snot. >> reporter: certainly one of the holy grails. the drug called qnexa. it's got one of the ingredients that was a diet drug taken off the market ten years ago and no good diet drugs since then that was phen-fen and worked pretty well and caused severe heart problems. this one has -- one of the ingredients of the first phen but not the second f 0e fen. the tests submitted to the fda shows that people at the highest doses lost 10% of their body weight along with diet and exercise and didn't suffer adverse consequen...

They're ever lifted on iran would he then have the ability to get at that $5 million? but there's an even bigger question. will he be around to collect it? because iranian intelligence agencies have obviously been following this very closely. saw that he had some freedoms on the internet to post videos and internet messages and the fact that he was paid $5 million belies his apparent claim that he was kidnapped and interrogated under pressure. >> yeah. he may have gotten a hero's welcome for the cameras but we'll see. jim miklaszewski at the pentagon for us, thanks very much. it is every die...

Demand for this. >> all right. staying on this fda news, yesterday they voted to keep this diabetes drug avandia on the market. that was a surprise. you and many others thought they were going to vote to pull it. >> they came close to taking it off the market. the groups brought together and very few of the people on the fda advisory panels are specialists in that disease so there were very few diabetes experts on it. some consumer reps or lawyers. some are different kinds of doctors and so they have a very long discussion and it goes back and forth. but in the end, most people were very convi...